Obermatt
See Similar Stocks →

Guerbet

PAR:GBT · FR0000032526
Health Care Equipment & SuppliesMedium

360

4
EV / EBIT47
Price / Owner Earnings65
Owner Earnings Yield1
Dividend Yield67
Price/Sales97
EV / Gross Profit100
Price/Book88
Return on Capital29
Cash Return on Capital19
Return on Equity12
EBIT Margin23
Gross Profitability90
Accruals91
Owner Earnings Margin21
Sales growth17
Profit Growth37
Long-Term EPS Growth7
Owner Earnings Growth5
Reinvestment81
Price momentum6
Debt load7
Refinancing96
Debt Payback1
Liquidity28
Analyst ratings5
Opinion Changes11
Price Target Upside41
Market mood15
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Guerbet doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryFrance
IndustryHealth Care Equipment & Supplies
SizeMedium
TypePublic Company
ExchangeENXTPA
Founded1926
Employees1,950
Websiteguerbet.com
ISINFR0000032526
Last UpdateApr 2, 2026
Indices
CAC All (France)Sound Pay Practices (Europe)
Themes
Health DiagnosticsUrologyBiomedical EngineeringArtificial IntelligenceOncologyMedicalPharmaceutical

Description

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. Business Segments The company operates through Contrast Media, Medical Devices, and Digital Solutions segments…

Analysis

Middle-of-the-road

Guerbet SA sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is fragile. The company scores 4/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
32
2023202420252026

All-time high

100

Apr 2025

All-time low

13

Mar 2026

Average rank

65

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
97
93
94
93
Price/Earnings
64
92
95
92
Price/Book
88
91
94
91
Dividend Yield
67
63
64
78
Value (overall)
95
100
95
99

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Guerbet with its peers
Laboratorios Farmaceuticos Rovi
MCE:ROVI
46
CountrySpain
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Pentixapharm
GER:PTP
22
CountryGermany
IndustryHealth Care Equipment & Supplies
SizeX-Small
Full Stock Analysis →
DiaSorin
MIL:DIA
34
CountryItaly
IndustryHealth Care Equipment & Supplies
SizeLarge
Full Stock Analysis →
ALK-Abelló
CPH:ALK B
83
CountryDenmark
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Immunovant
NSQ:IMVT
86
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Virbac
PAR:VIRP
58
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →